Abstract
We investigated the effect of a 5-day low-dose ritonavir therapy, as it is used in the treatment of COVID-19 with nirmatrelvir/ritonavir, on the pharmacokinetics of three factor Xa inhibitors (FXaI). Concurrently, the time course of the activities of the cytochromes P450 (CYP) 3A4, 2C19, and 2D6 was assessed. In an open-label, fixed sequence clinical trial, the effect and duration of a 5-day oral ritonavir (100mg twice daily) treatment on the pharmacokinetics of three oral microdosed FXaI (rivaroxaban 25µg, apixaban 25µg, and edoxaban 50µg) and microdosed probe drugs (midazolam 25µg, yohimbine 50µg, and omeprazole 100µg) was evaluated in eight healthy volunteers. The plasma concentrations of all drugs were quantified using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods and pharmacokinetics were analysed using non-compartmental analyses. Ritonavir increased the exposure of apixaban, edoxaban, and rivaroxaban, but to a different extent the observed area under the plasma concentration-time curve (geometric mean ratio 1.29, 1.46, and 1.87, respectively). A strong CYP3A4 inhibition (geometric mean ratio >10), a moderate CYP2C19 induction 2days after ritonavir (0.64), and no alteration of CYP2D6 were observed. A CYP3A4 recovery half-life of 2.3days was determined. This trial with three microdosed FXaI suggests that at most the rivaroxaban dose should be reduced during short-term ritonavir, and only in patients receiving high maintenance doses. Thorough time series analyses demonstrated differential effects on three different drug-metabolising enzymes over time with immediate profound inhibition of CYP3A4 and only slow recovery after discontinuation. EudraCT number: 2021-006643-39.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have